27 - 28 October, 2020
| Online Event
Webinar Day Two
12:50 pm - 1:00 pm
Chairperson's Opening Address
1:00 pm - 1:40 pm
Connecting Pharma with the Pharmacist: Roche’s Platform for Integration and Information
Dr. Philipp Schlatter -
Community of Practice Leader, Post Trial Access & Drug Supply,
Roche
1:40 pm - 2:20 pm
Session Reserved for Clinigen
2:20 pm - 3:00 pm
Panel Discussion: Building a Proactive Development Strategy to Avoid Reactive Decisions Across Your Route to Market
Nisha Shaunak -
Lead Pharmacist for Oncology, Guy’s and St Thomas’ & Specialised Cancer Commissioning Pharmacist,
NHS England
Nisha Shaunak
Lead Pharmacist for Oncology, Guy’s and St Thomas’ & Specialised Cancer Commissioning PharmacistNHS England
2:20 pm - 3:00 pm
Session To Be Announced
3:40 pm - 4:40 pm
Co-Creating Expanded Access Resources: Transforming information for transparency
Christine MacCracken -
Director, Patient Strategies & Solutions, Office of the Chief Medical Officer,
Janssen
In this session, you will have the opportunity to:
- Discuss experiences in identifying potential treatment options
- Review and provide input into new EA patient resource
- Join a global dialogue about EA
Christine MacCracken
Director, Patient Strategies & Solutions, Office of the Chief Medical OfficerJanssen
4:40 pm - 5:20 pm
Session To Be Announced
5:20 pm - 6:00 pm
Panel Discussion: Is there one standard for Covid and one for other therapeutic areas?
Alison Bateman-House -
Co-Chair,
NYU Working Group on Compassionate Use and Preapproval Access (CUPA)
Pat Furlong - Founding President & CEO, Parent Project Muscular Dystrophy (PPMD) and CUPA Member
Kenneth Moch - President & CEO, Cognition Therapeutics and CUPA Member
A discussion from multiple stakeholder perspectives on what’s currently happening in various therapeutic areas with all the attention current being focused on COVID-19. Focus topics will include the conduct of trials, investment into new research, patient engagement and regulatory pathways.
The central question to be asked will be: How do we justify what we are doing under – and with - Covid in comparison to what we are doing for other diseases?
Alison Bateman-House
Co-ChairNYU Working Group on Compassionate Use and Preapproval Access (CUPA)
Pat Furlong
Founding President & CEOParent Project Muscular Dystrophy (PPMD) and CUPA Member
